Immunogenicity and Safety of a China-Made Monovalent Pandemic (H1N1) 2009 Influenza A Vaccine in Healthcare Workers in Guangzhou, China

DOI Web Site Web Site
  • Zhan Yangqing
    Department of Respiratory Medicine of the First Affiliated Hospital of Guangzhou Medical College, State Key Laboratory of Respiratory Disease (Guangzhou Medical University), China
  • Yang Zifeng
    The First Affiliated Hospital of Guangzhou Medical College, Division of Clinical Virology of State Key Laboratory of Respiratory Disease (Guangzhou Medical University), China
  • Li Lianna
    Section of Inner Infection Prevention of the First Affiliated Hospital of Guangzhou Medical College, China
  • Ye Dan
    Prevention and Health Section of the First Affiliated Hospital of Guangzhou Medical College, China
  • Wu Huiyan
    The First Affiliated Hospital of Guangzhou Medical College, Division of Clinical Virology of State Key Laboratory of Respiratory Disease (Guangzhou Medical University), China
  • Fu Renzhen
    The First Affiliated Hospital of Guangzhou Medical College, Division of Clinical Virology of State Key Laboratory of Respiratory Disease (Guangzhou Medical University), China
  • Zhao Suishan
    The First Affiliated Hospital of Guangzhou Medical College, Division of Clinical Virology of State Key Laboratory of Respiratory Disease (Guangzhou Medical University), China
  • Wang Yutao
    The First Affiliated Hospital of Guangzhou Medical College, Division of Clinical Virology of State Key Laboratory of Respiratory Disease (Guangzhou Medical University), China
  • Zhou Rong
    The First Affiliated Hospital of Guangzhou Medical College, Division of Clinical Virology of State Key Laboratory of Respiratory Disease (Guangzhou Medical University), China
  • Chen Rongchang
    Department of Respiratory Medicine of the First Affiliated Hospital of Guangzhou Medical College, State Key Laboratory of Respiratory Disease (Guangzhou Medical University), China

この論文をさがす

抄録

<p>Because healthcare workers played an important role in the battle against novel pandemic (H1N1) 2009 influenza, a clinical study was conducted to examine the immunogenicity and safety of a single dose of a China-made monovalent, split-virus, pandemic (H1N1) 2009 influenza vaccine in this special high-risk population. Healthcare workers in the First Affiliated Hospital of Guangzhou Medical College who received the pandemic (H1N1) 2009 influenza vaccine were prospectively enrolled. Antibody titers were measured at enrollment and 14 days later using hemagglutination-inhibition (HI) and microneutralization assays. Adverse events were recorded within 7 days and 6 months after vaccination. Double sera were provided by 51 of 65 enrolled subjects. Postvaccination titers of 1:40 or more on HI assay were observed in 96% of recipients. Seroconversion or a significant increase in titer on HI assay occurred in 59% of subjects. The factor increase in GMTs was 4.3. The majority of complaints were mild to moderate in intensity. Although more than half of healthcare workers seemed immune to the pandemic (H1N1) influenza A virus before vaccination, most of the subjects still showed a fast, robust immune response to a single 15-μg dose of a monovalent, split-virus unadjuvanted pandemic H1N1 2009 influenza vaccine.<tt> </tt></p>

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ